182 related articles for article (PubMed ID: 31344603)
1. Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis.
Mudhune GH; Armour M; McBride KA
Breast; 2019 Oct; 47():43-55. PubMed ID: 31344603
[TBL] [Abstract][Full Text] [Related]
2. The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: A systematic review.
Wang Y; Lewin N; Qaoud Y; Rajaee AN; Scheer AS
Breast; 2018 Aug; 40():123-130. PubMed ID: 29763858
[TBL] [Abstract][Full Text] [Related]
3. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.
Poggio F; Del Mastro L; Bruzzone M; Ceppi M; Razeti MG; Fregatti P; Ruelle T; Pronzato P; Massarotti C; Franzoi MA; Lambertini M; Tagliamento M
Breast Cancer Res Treat; 2022 Jan; 191(2):269-275. PubMed ID: 34731351
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.
Col NF; Hirota LK; Orr RK; Erban JK; Wong JB; Lau J
J Clin Oncol; 2001 Apr; 19(8):2357-63. PubMed ID: 11304788
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
Fahlén M; Fornander T; Johansson H; Johansson U; Rutqvist LE; Wilking N; von Schoultz E
Eur J Cancer; 2013 Jan; 49(1):52-9. PubMed ID: 22892060
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.
Col NF; Kim JA; Chlebowski RT
Breast Cancer Res; 2005; 7(4):R535-40. PubMed ID: 15987460
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality.
Durna EM; Wren BG; Heller GZ; Leader LR; Sjoblom P; Eden JA
Med J Aust; 2002 Oct; 177(7):347-51. PubMed ID: 12358575
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
9. The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors.
Welnicka-Jaskiewicz M; Jassem J
Cancer Treat Rev; 2003 Oct; 29(5):355-61. PubMed ID: 12972354
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
O'Meara ES; Rossing MA; Daling JR; Elmore JG; Barlow WE; Weiss NS
J Natl Cancer Inst; 2001 May; 93(10):754-62. PubMed ID: 11353785
[TBL] [Abstract][Full Text] [Related]
11. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy.
Manjer J; Malina J; Berglund G; Bondeson L; Garne JP; Janzon L
Int J Cancer; 2001 Jun; 92(6):919-22. PubMed ID: 11351317
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies.
Yu X; Zhou S; Wang J; Zhang Q; Hou J; Zhu L; He Y; Zhao J; Zhong S
Breast Cancer; 2017 Sep; 24(5):643-657. PubMed ID: 28601917
[TBL] [Abstract][Full Text] [Related]
14. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy (HT) in patients with breast cancer.
Batur P; Blixen CE; Moore HC; Thacker HL; Xu M
Maturitas; 2006 Jan; 53(2):123-32. PubMed ID: 16368466
[TBL] [Abstract][Full Text] [Related]
16. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer.
Chlebowski RT; McTiernan A
J Clin Oncol; 1999 Jan; 17(1):130-42. PubMed ID: 10458226
[TBL] [Abstract][Full Text] [Related]
17. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
19. The Stockholm trial of HRT in breast cancer survivors.
Brown S
J Br Menopause Soc; 2005 Jun; 11(2):41-2. PubMed ID: 15970013
[No Abstract] [Full Text] [Related]
20. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.
Tan YH; Lethaby A
Cochrane Database Syst Rev; 2013 Nov; (11):CD010241. PubMed ID: 24234875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
